Ginger can be used in adjuvant treatment of pain in TACE patients: A randomized, double-blind, placebo-controlled Phase ? clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13004305

Enrollment

Unknown

Registered

2013-12-20

Start date

2014-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Experimental group:Oral ginger capsules

Control group:Oral placebo capsules

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 70 years; patients who fit the diagnosis of liver cancer, no pain complained, or pain score = 3; ECOG score 0-2; expected survival of = 3 months; able to follow the program required visits / treatment protocols; subjects were enrolled into this study and signed an informed consent form, good compliance with follow-up.

Exclusion criteria

Exclusion criteria: Secondary liver cancer; does not fit the Inclusion criteria, specifically bone metastasis; have TACE surgery contraindications; 18 years of age or 75 years of age.

Design outcomes

Primary

Measure	Time frame
The time of the pain occur;Intensity of the pain;	—

Countries

China

Contacts

Public ContactLi Dong

The First People's Hospital of Changzhou

cattail26@sina.com+86 13775172668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026